141 related articles for article (PubMed ID: 33549644)
1. The role of combined ion-beam radiotherapy (CIBRT) with protons and carbon ions in a multimodal treatment strategy of inoperable osteosarcoma.
Seidensaal K; Mattke M; Haufe S; Rathke H; Haberkorn U; Bougatf N; Kudak A; Blattmann C; Oertel S; Kirchner M; Buesch C; Kieser M; Herfarth K; Kulozik A; Debus J; Uhl M; Harrabi SB
Radiother Oncol; 2021 Jun; 159():8-16. PubMed ID: 33549644
[TBL] [Abstract][Full Text] [Related]
2. Inoperable or incompletely resected craniofacial osteosarcoma treated by particle radiotherapy.
Seidensaal K; Dostal M; Liermann J; Adeberg S; Weykamp F; Schmid MP; Freudlsperger C; Hoffmann J; Hompland I; Herfarth K; Debus J; Harrabi SB
Front Oncol; 2022; 12():927399. PubMed ID: 36212490
[TBL] [Abstract][Full Text] [Related]
3. Non-randomized therapy trial to determine the safety and efficacy of heavy ion radiotherapy in patients with non-resectable osteosarcoma.
Blattmann C; Oertel S; Schulz-Ertner D; Rieken S; Haufe S; Ewerbeck V; Unterberg A; Karapanagiotou-Schenkel I; Combs SE; Nikoghosyan A; Bischof M; Jäkel O; Huber P; Kulozik AE; Debus J
BMC Cancer; 2010 Mar; 10():96. PubMed ID: 20226028
[TBL] [Abstract][Full Text] [Related]
4. High control rates of proton- and carbon-ion-beam treatment with intensity-modulated active raster scanning in 101 patients with skull base chondrosarcoma at the Heidelberg Ion Beam Therapy Center.
Mattke M; Vogt K; Bougatf N; Welzel T; Oelmann-Avendano J; Hauswald H; Jensen A; Ellerbrock M; Jäkel O; Haberer T; Herfarth K; Debus J; Uhl M
Cancer; 2018 May; 124(9):2036-2044. PubMed ID: 29469932
[TBL] [Abstract][Full Text] [Related]
5. Particle Therapy Using Protons or Carbon Ions for Unresectable or Incompletely Resected Bone and Soft Tissue Sarcomas of the Pelvis.
Demizu Y; Jin D; Sulaiman NS; Nagano F; Terashima K; Tokumaru S; Akagi T; Fujii O; Daimon T; Sasaki R; Fuwa N; Okimoto T
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):367-374. PubMed ID: 28463156
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and feasibility of re-irradiation using carbon ions for pancreatic cancer that recurs after carbon-ion radiotherapy.
Hagiwara Y; Yamada S; Isozaki Y; Takiyama H; Shinoto M; Kawashiro S; Bhattacharyya T; Nemoto K; Tsuji H
Clin Transl Radiat Oncol; 2021 Jan; 26():24-29. PubMed ID: 33294643
[TBL] [Abstract][Full Text] [Related]
7. Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma.
Ciernik IF; Niemierko A; Harmon DC; Kobayashi W; Chen YL; Yock TI; Ebb DH; Choy E; Raskin KA; Liebsch N; Hornicek FJ; Delaney TF
Cancer; 2011 Oct; 117(19):4522-30. PubMed ID: 21448934
[TBL] [Abstract][Full Text] [Related]
8. Long-term survival of two patients with inoperable post-irradiation osteosarcoma treated with carbon-ion radiotherapy: a case report.
Shiba S; Okamoto M; Yanagawa T; Kohama I; Shibuya K; Okazaki S; Miyasaka Y; Chikuda H; Ohno T
Radiat Oncol; 2022 Apr; 17(1):68. PubMed ID: 35379287
[TBL] [Abstract][Full Text] [Related]
9. Randomised trial of proton vs. carbon ion radiation therapy in patients with low and intermediate grade chondrosarcoma of the skull base, clinical phase III study.
Nikoghosyan AV; Rauch G; Münter MW; Jensen AD; Combs SE; Kieser M; Debus J
BMC Cancer; 2010 Nov; 10():606. PubMed ID: 21050498
[TBL] [Abstract][Full Text] [Related]
10. A randomized controlled phase III study comparing hadrontherapy with carbon ions versus conventional radiotherapy - including photon and proton therapy - for the treatment of radioresistant tumors: the ETOILE trial.
Balosso J; Febvey-Combes O; Iung A; Lozano H; Alloh AS; Cornu C; Hervé M; Akkal Z; Lièvre M; Plattner V; Valvo F; Bono C; Fiore MR; Vitolo V; Vischioni B; Patin S; Allemand H; Gueyffier F; Margier J; Guerre P; Chabaud S; Orecchia R; Pommier P
BMC Cancer; 2022 May; 22(1):575. PubMed ID: 35606739
[TBL] [Abstract][Full Text] [Related]
11. Acute Toxicity and Quality of Life in Patients With Prostate Cancer Treated With Protons or Carbon Ions in a Prospective Randomized Phase II Study--The IPI Trial.
Habl G; Uhl M; Katayama S; Kessel KA; Hatiboglu G; Hadaschik B; Edler L; Tichy D; Ellerbrock M; Haberer T; Wolf MB; Schlemmer HP; Debus J; Herfarth K
Int J Radiat Oncol Biol Phys; 2016 May; 95(1):435-443. PubMed ID: 27084659
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the CLEOPATRA trial.
Combs SE; Kieser M; Rieken S; Habermehl D; Jäkel O; Haberer T; Nikoghosyan A; Haselmann R; Unterberg A; Wick W; Debus J
BMC Cancer; 2010 Sep; 10():478. PubMed ID: 20819220
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
[TBL] [Abstract][Full Text] [Related]
14. The impact of age on the outcome of patients treated with radiotherapy for mucoepidermoid carcinoma (MEC) of the salivary glands in the head and neck: A 15-year single-center experience.
Akbaba S; Heusel A; Mock A; Held T; Lang K; Hoerner-Rieber J; Forster T; Katayama S; Kargus S; Rieken S; Plinkert P; Herfarth K; Debus J; Adeberg S
Oral Oncol; 2019 Oct; 97():115-123. PubMed ID: 31494395
[TBL] [Abstract][Full Text] [Related]
15. Adenoid cystic Carcinoma and Carbon ion Only irradiation (ACCO): Study protocol for a prospective, open, randomized, two-armed, phase II study.
Lang K; Adeberg S; Harrabi S; Held T; Kieser M; Debus J; Herfarth K
BMC Cancer; 2021 Jul; 21(1):812. PubMed ID: 34266402
[TBL] [Abstract][Full Text] [Related]
16. Carbon ion radiotherapy for inoperable pediatric osteosarcoma.
Mohamad O; Imai R; Kamada T; Nitta Y; Araki N;
Oncotarget; 2018 May; 9(33):22976-22985. PubMed ID: 29796166
[TBL] [Abstract][Full Text] [Related]
17. Hypofractionated proton and carbon ion beam radiotherapy for sacrococcygeal chordoma (ISAC): An open label, randomized, stratified, phase II trial.
Seidensaal K; Froehlke A; Lentz-Hommertgen A; Lehner B; Geisbuesch A; Meis J; Liermann J; Kudak A; Stein K; Uhl M; Tessonnier T; Mairani A; Debus J; Herfarth K
Radiother Oncol; 2024 Jun; ():110418. PubMed ID: 38944346
[TBL] [Abstract][Full Text] [Related]
18. The role of
Angelini A; Ceci F; Castellucci P; Graziani T; Polverari G; Trovarelli G; Palmerini E; Ferrari S; Fanti S; Ruggieri P
Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1712-1720. PubMed ID: 28405727
[TBL] [Abstract][Full Text] [Related]
19. COSMIC: A Regimen of Intensity Modulated Radiation Therapy Plus Dose-Escalated, Raster-Scanned Carbon Ion Boost for Malignant Salivary Gland Tumors: Results of the Prospective Phase 2 Trial.
Jensen AD; Nikoghosyan AV; Lossner K; Haberer T; Jäkel O; Münter MW; Debus J
Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):37-46. PubMed ID: 26279022
[TBL] [Abstract][Full Text] [Related]
20. Maximum standardized uptake value on FDG-PET predicts survival in stage I non-small cell lung cancer following carbon ion radiotherapy.
Shirai K; Abe T; Saitoh JI; Mizukami T; Irie D; Takakusagi Y; Shiba S; Okano N; Ebara T; Ohno T; Nakano T
Oncol Lett; 2017 Jun; 13(6):4420-4426. PubMed ID: 28588712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
